Cure My Disease

Don't miss your cure!

 Log in / Sign up

MRI-Targeted biopsies may outshine standard needle probes for aggressive prostate cancer

NCT ID NCT02485379

Diagnosis Sponsor: Hospices Civils de Lyon Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compared two ways to biopsy the prostate in 275 men with suspected cancer. The standard method takes random samples from the gland, which can miss aggressive tumors or find harmless ones. The new method uses MRI images to guide the needle to suspicious spots. The goal was to see if MRI-targeted biopsies catch more aggressive cancers (Gleason score 7 or higher) than the standard approach.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could make MRI-targeted biopsy the new standard for detecting aggressive prostate cancer, reducing missed diagnoses and unnecessary treatments.
What could go wrong
This is a completed diagnostic study, not a treatment trial. Results may not change practice if they show only modest improvement or if MRI is not widely available.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

275 people

The number who actually took part.

Start date

Jul 2015

Finished

Nov 2016

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient referred for prostate mp-MRI before a first set of prostate biopsies, with a planned time interval of less than 3 months between MRI and biopsies * Age ≤75 years * PSA level ≤20 ng/mL * Clinical stage ≤T2c * Patient insured under the French social security system or beneficiary of an equivalent regime Exclusion Criteria: * Contraindication to transrectal biopsy * Contraindication to MRI * History of hip prosthesis * History of androgen deprivation therapy * Patients with history of prostate cancer diagnosed on TURP * Patients with history of pelvic radiation therapy (whatever the reason) * Patient deprived of freedom following a court or administrative order * Patient under guardianship or under legal guardianship

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Prostate cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Prostate cancer

Contacts and locations

Locations

  • CHU Nancy Brabois

    Vandœuvre-lès-Nancy, 54511, France

  • CHU de Saint-Etienne

    Saint-Etienne, 42055, France

  • CLIMAL (Centre Libéral Imagerie Médicale Agglomération Lille)

    Lille, 59700, France

  • Centre Hospitalier Lyon Sud

    Pierre-Bénite, 69495, France

  • Centre Hospitalier St Joseph St Luc

    Lyon, 69365, France

  • Clinique Jules Verne

    Nantes, 44300, France

  • Clinique Urologique Nantes Atlantis

    Saint-Herblain, 44815, France

  • Groupe Hospitalier Pellegrin - CHU de Bordeaux

    Bordeaux, 33076, France

  • Hopital Pitie Salpetriere

    Paris, 75013, France

  • Hôpital Cochin

    Paris, 75014, France

  • Hôpital Edouard Herriot

    Lyon, 69437, France

  • Hôpital Européen Georges Pompidou

    Paris, 75015, France

  • Hôpital Huriez - CHU de Lille

    Lille, 59037, France

  • Hôpital Michallon - CHU de Grenoble

    Grenoble, 38043, France

  • Hôpital Necker

    Paris, 75015, France

  • Hôpital Privé La Louvière

    Lille, 59042, France

  • IRMAS

    Saint-Priest-en-Jarez, 42270, France

  • Institut Paoli Calmettes

    Marseille, 13273, France

  • Institut Universitaire du Cancer de Toulouse (IUCT) Oncopole - CHU de Toulouse

    Toulouse, 31059, France

  • Nouvel Hopital Civil - CHU de Strasbourg

    Strasbourg, 67091, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.